Table 2.
Observed (Obs) and expected (Exp) numbers and standardized incidence ratios (SIRs) of cancer among patients with IgA deficiency or CVID in Denmark and Sweden
| Combined cohort (n = 562) | Danish patients (n = 64) | Swedish patients (n = 498) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer site | Obs | Exp | SIR | 95% CI | Obs | Exp | SIR | 95% CI | Obs | Exp | SIR | 95% CI |
| All malignant neoplasms | 28 | 21·3 | 1·3 | 0·9–1·9 | 5 | 2·0 | 2·5 | 0·8–5·9 | 23 | 19·2 | 1·2 | 0·8–1·8 |
| Buccal cavity and pharynx | 1 | 0·4 | 2·4 | 0·1–13·3 | 0 | 0·0 | – | 0·0–92·2 | 1 | 0·4 | 2·7 | 0·0–14·8 |
| Digestive system | 9 | 4·3 | 2·1 | 1·0–4·0 | 1 | 0·3 | 3·4 | 0·0–19·1 | 81 | 4·0 | 2·0 | 0·9–4·0 |
| Stomach | 5 | 0·7 | 7·5 | 2·4–17·4 | 1 | 0·0 | 26·3 | 0·3–147 | 4 | 0·6 | 6·3 | 1·7–16·1 |
| Lung | 0 | 1·5 | – | 0·0–2·4 | 0 | 0·2 | – | 0·0–17·6 | 0 | 1·3 | – | 0·0–2·8 |
| Breast | 0 | 3·5 | – | 0·0–1·1 | 0 | 0·4 | – | 0·0–10·9 | 0 | 3·1 | – | 0·0–1·2 |
| Female genital organs | 3 | 2·0 | 1·5 | 0·3–4·4 | 0 | 0·2 | – | 0·0–16·8 | 32 | 1·8 | 1·7 | 0·3–4·9 |
| Male genital organs | 2 | 2·0 | 1·0 | 0·1–3·6 | 0 | 0·1 | – | 0·0–46·1 | 2 | 1·9 | 1·0 | 0·1–3·8 |
| Urinary system | 2 | 1·6 | 1·3 | 0·2–4·6 | 0 | 0·1 | – | 0·0–30·7 | 2 | 1·5 | 1·4 | 0·2–5·0 |
| Skin | 1 | 1·8 | 0·6 | 0·0–3·2 | 0 | 0·3 | – | 0·0–11·2 | 1 | 1·4 | 0·7 | 0·0–3·9 |
| Brain and nervous system | 2 | 0·9 | 2·3 | 0·3–8·3 | 1 | 0·1 | 9·8 | 0·1–54·3 | 1 | 0·8 | 1·3 | 0·0–7·3 |
| Endocrine glands3 | 1 | 0·4 | 2·3 | 0·1–12·7 | 0 | 0·0 | – | 1·7–51·6 | 14 | 0·4 | 2·3 | 0·0–12·6 |
| Hematopoietic and lymphatic system | 5 | 1·6 | 3·2 | 1·0–7·5 | 2 | 0·2 | 13·3 | 1·6–48·2 | 3 | 1·4 | 2·2 | 0·4–6·3 |
| Non-Hodgkin's lymphoma | 4 | 0·7 | 6·0 | 1·6–15·3 | 2 | 0·1 | 40·0 | 4·8–144 | 2 | 0·6 | 3·2 | 0·4–11·7 |
| Hodgkin's disease | 1 | 0·1 | 7·1 | 0·2–39·8 | 0 | 0·0 | – | 0·0–184 | 1 | 0·1 | 8·1 | 0·1–45·3 |
| Leukaemia | 0 | 0·5 | – | 0·0–7·7 | 0 | 0·1 | – | 0·0–61·5 | 0 | 0·4 | – | 0·0–8·8 |
| Other specified sites | 0 | 0·8 | – | 0·0–4·8 | 0 | 0·1 | – | 0·0–46·1 | 0 | 0·7 | – | 0·0–5·3 |
| Metastases and unspecified sites | 2 | 0·6 | 3·2 | 0·4–11·5 | 1 | 0·0 | 24·8 | 0·3–138 | 1 | 0·6 | 1·7 | 0·0–9·5 |
1
Cancer of the large intestine (n = 2) and pancreas (n = 2) in addition to the stomach cancers.
2
Cancer of the corpus uteri (n = 2) and ovary (n = 1).
3
Not including thymomas.
4
Cancer of the parathyroid gland significantly elevated SIRs are marked bold (P < 0·05).